Table 3:
Antibiotic | Sensitivity (%) | Specificity (%) | % agreement (CI) | PPV (100%) | NPV (100%) |
---|---|---|---|---|---|
Ampicillin | 100 | N/A | 100 (91.2– 100) | 100 | N/A |
Ceftriaxone | 100 | N/A | 100 (91.2– 100) | 100 | N/A |
Ceftazidime | 100 | N/A | 100 (91.2–100) | 100 | N/A |
TMP/SMX | 91.9 | 33.3 | 87.5 (73.2–95.8) | 94.4 | 25 |
Ciprofloxacin | 97.3 | 66.6 | 95 (83.1–99.4) | 97.3 | 66.67 |
Gentamicin | 24.1 | 100 | 45 (29.2–61.5) | 100 | 33.3 |
Meropenem | 100 | N/A | 100 (91.2–100) | 100 | N/A |
Levofloxacin | 100 | 100 | 100 (91.19–100) | 100 | 100 |
Cefepime | 100 | N/A | 97.5 (86.8–99.9) | 97.5 | N/A |
Tobramycin | 100 | 100 | 100 (91.2– 100) | 100 | 100 |
Ertapenem | 100 | N/A | 100 (91.2– 100) | 100 | N/A |
Cefazolin | 100 | N/A | 100 (91.2– 100) | 100 | N/A |
Aztreonam | 100 | N/A | 100 (91.2– 100) | 100 | N/A |
Total | 94.7 | 88 | 94.4 (92.0–96.2) | 99.4 | 45.8 |
PPV, positive predictive value; NPV, negative predictive value; CI, confidence intervals; N/A, not available